ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas

PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

July 31, 2000

Primary Completion Date

December 31, 2000

Conditions
Pancreatic Cancer
Interventions
DRUG

ISIS 2503

Beginning dosage of ISIS 2503 is 6 mg/kg/day given as a continuous i.v. infusion over the first 14 days of a 21-day treatment cycle. This will be repeated for the first two weeks of every three-week treatment cycle.

Trial Locations (2)

35294

University of Alabama Comprehensive Cancer Center, Birmingham

03756

Norris Cotton Cancer Center, Lebanon

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Ionis Pharmaceuticals, Inc.

INDUSTRY

lead

University of Alabama at Birmingham

OTHER